GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Paliperidone palmitate - INVEGA TRINZA three-month injection

Local official-label summaryBase record retrieved 2026-09-08See the evidence for this drug2 sources available - open source summaries, references and comparisons

INVEGA TRINZA / INVEGA TRINZA injection / paliperidone palmitate

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
TRINZA: renal eligibility does not supply a switching schedule

The selected renal passages require prior adjustment and stabilization on the one-month formulation. They do not establish immediate interchangeability among all paliperidone products.

Before applying: Verify the complete transition and missed-dose instructions for this formulation before use.

Also check: TRINZA: renal eligibility does not supply a switching schedule

Official source

Paliperidone palmitate - INVEGA TRINZA three-month injection

Product / population
Adults; INVEGA TRINZA intramuscular three-month suspension after appropriate prior paliperidone treatment.
Renal measure
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.

PI revision not established from the selected source sections.

Renal dosing, restrictions and evidence limits

For mild renal impairment, CrCl 50 to <80, adjust and stabilize the one-month paliperidone palmitate injection before transitioning to TRINZA. Use is not recommended when CrCl is <50. This is a renal supplement, not a complete conversion or missed-dose protocol.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c39e65d7-fa44-4e4c-8b12-a654d3ed0eae

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Paliperidone palmitate - INVEGA TRINZA three-month injection

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adults; INVEGA TRINZA intramuscular three-month suspension after appropriate prior paliperidone treatment.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - INVEGA TRINZA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adults; INVEGA TRINZA intramuscular three-month suspension after appropriate prior paliperidone treatment.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

formulation scope

TRINZA: renal eligibility does not supply a switching schedule

The selected renal passages require prior adjustment and stabilization on the one-month formulation. They do not establish immediate interchangeability among all paliperidone products.

How to use this: Verify the complete transition and missed-dose instructions for this formulation before use.

GlobalRPh RX List - INVEGA TRINZAPaliperidone palmitate - INVEGA TRINZA three-month injectionPaliperidone palmitate - INVEGA SUSTENNA monthly injectionPaliperidone palmitate - INVEGA HAFYERA six-month injectionPaliperidone

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePaliperidone palmitate - INVEGA TRINZA three-month injectionGlobalRPh RX List - INVEGA TRINZA
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/invega-trinza-drug/

Exact product and population

Adults; INVEGA TRINZA intramuscular three-month suspension after appropriate prior paliperidone treatment.

RDM44-SCOPE-paliperidone-invega-trinza · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Paliperidone palmitate - INVEGA TRINZA three-month injection

Open original reference

Open / share this exact local source

DailyMed / Janssen Pharmaceuticals, Inc. · Adults; INVEGA TRINZA intramuscular three-month suspension after appropriate prior paliperidone treatment.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For mild renal impairment, CrCl 50 to <80, adjust and stabilize the one-month paliperidone palmitate injection before transitioning to TRINZA. Use is not recommended when CrCl is <50. This is a renal supplement, not a complete conversion or missed-dose protocol.

RDM44-official-paliperidone-invega-trinza-89702a3db0-C1 · Source locator: Dosage and Administration: Patients with Renal Impairment; Use in Specific Populations: Renal Impairment.

Source-specific limits

PI revision not established from the selected source sections.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c39e65d7-fa44-4e4c-8b12-a654d3ed0eae
Retrieved
2026-09-08
Exact label title
Paliperidone palmitate - INVEGA TRINZA three-month injection
DailyMed Set ID
c39e65d7-fa44-4e4c-8b12-a654d3ed0eae
Labeler
Janssen Pharmaceuticals, Inc.
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
b403239ccd3077699746e2e25bdc4eb77476718ced538f6bad16bcef6821b892
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - INVEGA TRINZA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adults; INVEGA TRINZA intramuscular three-month suspension after appropriate prior paliperidone treatment.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For CrCl 50 to <80, first adjust and stabilize treatment using the one-month paliperidone palmitate product before transition. Use is not recommended at CrCl <50. These selected renal instructions are not a complete switching, missed-dose or administration schedule.

RDM44-rxlist-paliperidone-invega-trinza-44fde801ee-C1 · Source locator: Dosage and Administration: Patients with renal impairment, lines 101-104.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/invega-trinza-drug/
Retrieved
2026-09-08
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min; not indexed laboratory eGFR.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
1face66bdf1bd93aa0b01748ce8320167bbb3c02f6dc35663561dab8249216d5

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/invega-trinza-drug/
Source retrieval
2026-09-08. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
e1026a5c04d0168265013766d5b71aa8bc6b5ebaf0d793228b6a5fa043b8cfa8
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report